Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has made a breakthrough in an ongoing study of Alzheimer’s disease. Their novel Alzheimer’s drug, buntanetap, which specifically targets neurotoxic proteins, has …
Groundbreaking Alzheimer’s Study Reveals Potential for Progression-Slowing Therapy Read More MALVERN, PA — In a recent financial report for 2023, Annovis Bio, Inc. (NYSE: ANVS) proclaimed progress in the battle against neurodegenerative diseases; however, the path to potential breakthroughs has …
Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials Read More MALVERN, PA — In a significant development for Alzheimer’s Disease (AD) research, Annovis Bio, Inc. (NYSE: ANVS) has unveiled new data from a study indicating that buntanetap, an innovative oral …
Annovis Bio’s Buntanetap Shows Promise in Early Alzheimer’s Disease Study Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biotech firm focused on developing novel treatments for neurodegenerative diseases, announced the successful completion of data cleaning for its pivotal phase …
Annovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaning Read More MALVERN, PA — Chester County-based Annovis Bio, Inc. (NYSE: ANVS) is set to make a significant impact at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) in Lisbon, …
Annovis Bio to Shed Light on Neurodegenerative Diseases at International Conference Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a Pennsylvania-based clinical-stage drug platform company, has announced the completion of the last patient visit in the phase II/III study of its …
Annovis Bio Wraps Up Phase II/III Trial for Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a leading biopharmaceutical company, announced this week the filing of a patent application that covers the use of buntanetap and its analogues …
Annovis Bio Files Patent for Novel Mental Illness Treatment Using Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS this week announced a delay in the release of Phase III study data for its promising Parkinson’s Disease drug, buntanetap. The postponement …
Annovis Bio Postpones Release of Phase III Data for Parkinson’s Disease Drug, Buntanetap Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More BERWYN, PA — In a recent announcement, Berwyn, Pennsylvania-based clinical-stage drug platform company Annovis Bio, Inc. (NYSE: ANVS) has appointed Andrew Walsh as its new Vice President of Finance. This …
Andrew Walsh Joins Annovis Bio as VP of Finance Amid Pivotal Clinical Trials Read More